In a new study, researchers found that long-term aspirin use before a diagnosis of colorectal cancer is linked to lower cancer death risk.
They found that pre-diagnosis aspirin use may help limit the metastatic spread of colorectal tumors before diagnosis.
Preventing distant metastases can lead to fewer deaths from colorectal cancer.
The research was conducted by a team at the American Cancer Society.
In the study, the team used data from men and women enrolled in the American Cancer Society’s Cancer Prevention Study-II (CPS-II) Nutrition Cohort.
These people were cancer-free at the year 1992/1993 and diagnosed with colorectal cancer during follow-up through 2015. Mortality outcomes were complete through to the end of 2016.
The study also examined the associations of pre-and post-diagnosis use of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) with cancer mortality among colon cancer survivors.
They found long-term aspirin use before a diagnosis of colorectal cancer is linked to lower cancer death risk.
The team says these findings are important because colorectal cancer patients seek guidance on lifestyle factors to improve their prognosis.
While more evidence is needed, findings from this study are an important resource to inform clinicians and cancer survivors about the potential benefits and harms of aspirin and non-aspirin NSAIDs use.
One author of the study is Peter T. Campbell, Ph.D.
The study is published in JNCI: The Journal of the National Cancer Institute.
Copyright © 2021 Knowridge Science Report. All rights reserved.
